Gang Wang

Director/Board Member en SHANGHAI JUNSHI BIOSCIENCES CO., LTD. .

67 años

Health Technology

Consumer Services

Perfil

Gang Wang is currently an Executive Director at Shanghai Junshi Biosciences Co., Ltd., an Independent Director at Hrain Biotechnology Co., Ltd., and an Independent Director at Obio Technology Shanghai Corp.
Ltd.
Dr. Wang obtained a doctorate degree from Dartmouth Medical School in 1995.

Cargos activos de Gang Wang

Empresas	Cargo	Inicio
SHANGHAI JUNSHI BIOSCIENCES CO., LTD.	Director/Board Member	20/10/2023
OBIO TECHNOLOGY (SHANGHAI) CORP., LTD.	Director/Board Member	29/12/2020
Hrain Biotechnology Co., Ltd. Hrain Biotechnology Co., Ltd. BiotechnologyHealth Technology Hrain Biotechnology Co., Ltd. engages in the research and development, and production of immune cell therapy products. It offers chimeric antigen receptor (CAR) T-cell therapy, chimeric antigen receptor-transduced natural killer (CAR-NK) cell therapy, dash chimeric antigen receptor (CAR) T-cell therapy. The company was founded by Pin Wang on July 20, 2015 and is headquartered in Shanghai, China.	Director/Board Member	18/06/2021

Todos los cargos activos de Gang Wang

Formación de Gang Wang.

Dartmouth Medical School

Doctorate Degree

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Gang Wang.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas	2
SHANGHAI JUNSHI BIOSCIENCES CO., LTD.	Health Technology
OBIO TECHNOLOGY (SHANGHAI) CORP., LTD.	Health Technology

Empresas privadas	1
Hrain Biotechnology Co., Ltd. Hrain Biotechnology Co., Ltd. BiotechnologyHealth Technology Hrain Biotechnology Co., Ltd. engages in the research and development, and production of immune cell therapy products. It offers chimeric antigen receptor (CAR) T-cell therapy, chimeric antigen receptor-transduced natural killer (CAR-NK) cell therapy, dash chimeric antigen receptor (CAR) T-cell therapy. The company was founded by Pin Wang on July 20, 2015 and is headquartered in Shanghai, China.	Health Technology